{
    "root": "203ed9ba-0b95-4ac7-a546-13be55385d5f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "KAZANO",
    "value": "20250226",
    "ingredients": [
        {
            "name": "ALOGLIPTIN BENZOATE",
            "code": "EEN99869SC"
        },
        {
            "name": "Metformin hydrochloride",
            "code": "786Z46389E"
        },
        {
            "name": "mannitol",
            "code": "3OWL53L36A"
        },
        {
            "name": "microcrystalline cellulose",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "magnesium stearate",
            "code": "70097M6I30"
        },
        {
            "name": "talc",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "titanium dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ferric oxide yellow",
            "code": "EX438O2MRT"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        }
    ],
    "indications": "KAZANO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "contraindications": "Individualize the starting dosage based on the patient's current regimen. ( 2.1 ) Given orally twice daily with food. ( 2.1 ) Adjust the dosage based on effectiveness and tolerability while not exceeding the maximum recommended daily dosage of 25 mg alogliptin and 2000 mg metformin HCl. ( 2.1 ) Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR). ( 2.2 ) Do not use in patients with eGFR below 60 mL/min/1.73 m 2 . KAZANO may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures. ( 2.3 )",
    "warningsAndPrecautions": "KAZANO tablets are available in the following strengths and packages:\n                  12.5 mg/500 mg tablet: pale yellow, oblong, film-coated tablets with \"12.5/500\" debossed on one side and \"322M\" debossed on the other side, available in:\n                  \n                     \n                     \n                     \n                        \n                             NDC 64764-335-60\n                           Bottles of 60 tablets\n                        \n                        \n                             NDC 64764-335-80\n                           Bottles of 180 tablets\n                        \n                        \n                             NDC 64764-335-77\n                           Bottles of 500 tablets\n                        \n                     \n                  \n                  12.5 mg/1000 mg tablet: pale yellow, oblong, film-coated tablets with \"12.5/1000\" debossed on one side and \"322M\" debossed on the other side, available in:\n                  \n                     \n                     \n                     \n                        \n                             NDC 64764-337-60\n                           Bottles of 60 tablets\n                        \n                        \n                             NDC 64764-337-80\n                           Bottles of 180 tablets\n                        \n                        \n                             NDC 64764-337-77\n                           Bottles of 500 tablets",
    "adverseReactions": "KAZANO is contraindicated in patients with:\n                  \n                     Severe renal impairment (eGFR below 30 mL/min/1.73 m2) [see Warnings and Precautions (5.1)].\n                     Acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma.\n                     History of serious hypersensitivity reaction to alogliptin or metformin or any of the excipients in KAZANO, such as anaphylaxis, angioedema and severe cutaneous adverse reactions [see Warnings and Precautions (5.4), Adverse Reactions (6.2)]."
}